RecruitingNot ApplicableNCT06077019

Role of Lung Function for Exercise Capacity in Well-trained Individuals

Role of Lung Function, Airway Inflammation and Bronchial Hyper Reactivity for Exercise Capacity in Well-trained Individuals


Sponsor

Morten Hostrup, PhD

Enrollment

60 participants

Start Date

Oct 3, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of the project is to investigate exercise performance in humans following prolonged inhalation of beta2-agonists vilanterol + fluticasone furoate or indacaterol + mometasone furoate


Eligibility

Min Age: 18 YearsMax Age: 39 Years

Inclusion Criteria3

  • Age 18-39
  • Physically active > 5 h weekly
  • Maximal oxygen consumption classified as high or very high

Exclusion Criteria10

  • Diagnosed with severe asthma and been in treatment with long-acting beta2-agonist/corticosteroid
  • ECG abnormality
  • ACQ score > 1.5
  • Severe bronchial hyperreactivity as determined by mannitol test
  • FEV1/FVC ratio < 0.7 determined with spirometry
  • Chronic illness determined to be a potential risk for participant during study
  • In chronic treatment with medication that may interfere with study results
  • Pregnancy
  • Smoker
  • Blood donation during the past 3 months

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVilanterol and Fluticasone Furoate

Participants inhale 25 µg vilanterol + fluticasone furoate daily

DRUGIndacaterol and Mometasone Furoate

Participants inhale 125 µg indacaterol + mometasone furoate daily

DRUGPlacebo

Participants inhale placebo daily


Locations(1)

August Krogh Building

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06077019


Related Trials